article thumbnail

STAT+: Amgen’s $27.8 billion Horizon merger is latest industry bet on pricey rare disease drugs

STAT

Amgen said Monday it would purchase Horizon Pharmaceuticals for $27.8 billion, marking the latest bet by a large pharmaceutical company on the lucrative market for treating a rare disease. However, Amgen is now a much larger company, with annual revenues of $26 billion and a market capitalization of almost $150 billion.

article thumbnail

Envision acquires commercial solutions firm Two Labs

pharmaphorum

Two Labs helps pharmaceutical companies develop and execute customised launch strategies for products. Envision’s acquisition of Two Labs follows the recent announcement of GHO Capital’s increased investment in the company and the backing of management for its continued global expansion.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Psychedelic medicines: are they gaining traction in Europe?

European Pharmaceutical Review

For example, the relaxed attitude towards cannabis in the Netherlands is well-known and Portugal has decriminalised the possession and consumption of all illicit substances since 2001. 6 Therefore, the quality of data provided to regulators will be key in obtaining MAs and subsequently marketing of psychedelic medicines.

article thumbnail

Bridging the healthcare digital divide: a gradual approach to adopting ePI

European Pharmaceutical Review

According to Eurostat, only 57 percent of people in the 55-74 age group use the internet regularly, and only 54 percent of Europeans possess basic digital skills The Pharmaceutical Group of the European Union (PGEU) presents a compelling argument against the proposed POD policy. References European Commission, (26 April 2023).

article thumbnail

Rare Disease Spotlight – tracing the rise of orphan drug designations over almost 40 years

Pharmaceutical Technology

A drug can also be considered for an orphan drug designation if a pharmaceutical company is unlikely to reclaim the research, development, and approval costs in addition to reasonable profit for a drug within seven years of an FDA approval.

article thumbnail

Fishawack Health welcomes expert-led dermatology initiative FIDE to its group

pharmaphorum

Established in 2001 and headquartered in the UK, the organization is powered by a 1,300+ globe-spanning pack of strategic, creative, and scientific experts. FIDE’s expert-led approach differs from conventional consultancy by providing biotechnology and pharmaceutical companies with direct and unfiltered healthcare professional engagement.

article thumbnail

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

pharmaphorum

At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”.